FTRE · Fortrea Holdings Inc. · Webcasts, Transcripts & Audio
$20.66
+0.16 (+0.78%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.98B
Shares
96.50M
Volume · Nov 19
273.39K
Avg daily vol (3M)
1.67M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Fortrea Holdings Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Fortrea Holdings Inc. (FTRE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-02
Fortrea Holdings Inc. (FTRE) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-12-01
Fortrea Holdings Inc. (FTRE) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-19
Fortrea Holdings Inc. (FTRE) November 19, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Fortrea Holdings Inc. (FTRE) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-29
Fortrea Holdings Inc. (FTRE) Q3 2026 Earnings Call Transcript
Confident tone
Margin expansion and operating leverage
Financial performance and guidance
China growth opportunity
Revenue
$691.50M
▼ 1.4% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-29
Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call Transcript
Positive tone
Guidance raise / financial performance
Commercial excellence and book-to-bill
Therapeutic and geographic mix
Revenue
$678.20M
▼ 4.5% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Fortrea Holdings Inc. (FTRE) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Fortrea Holdings Inc. (FTRE) Q1 2026 Earnings Call Transcript
Positive tone
Biotech demand recovery
Guidance and revenue conversion timing
Commercial execution and book-to-bill
Revenue
$636.50M
▼ 2.3% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Fortrea Holdings Inc. (FTRE) Q4 2025 Earnings Call Transcript
Positive tone
Clinical pharmacology and FSP dynamics
Bookings and demand recovery
Commercial framework (3Rs)
Revenue
$660.50M*
▼ 5.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Fortrea Holdings Inc. (FTRE) Q3 2025 Earnings Call Transcript
Positive tone
FSP business and pricing discipline
Backlog and book-to-bill
Clinical pharmacology and new awards
Revenue
$701.30M
▲ 3.9% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Fortrea Holdings Inc. (FTRE) Q2 2025 Earnings Call
Balanced tone
Margin optimization and cost initiatives
Guidance update
Bookings and book-to-bill weakness
Revenue
$710.30M
▲ 7.2% YoY Diluted EPS
$-4.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Fortrea Holdings Inc. (FTRE) Q1 2025 Earnings Call Transcript
Positive tone
Bookings and pipeline
SG&A cost reduction
Gross margin and project ramp
Revenue
$651.30M
▼ 1.6% YoY Diluted EPS
$-6.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Fortrea Holdings Inc. (FTRE) Q4 2024 Earnings Call Transcript
Cautious tone
2025 guidance and profitability shortfall
Operational restructuring and cost actions
Capacity utilization and resourcing
Revenue
$697.00M*
▼ 1.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Fortrea Holdings Inc. (FTRE) Q3 2024 Earnings Call Transcript
Positive tone
Biotech and Large Pharma Mix
Bookings and Book-to-Bill
Clinical Pharmacology (CPS/Phase 1)
Revenue
$674.90M
▼ 5.4% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Fortrea Holdings Inc. (FTRE) Q2 2024 Earnings Call Transcript
Positive tone
Biotech contracting unpredictability
Large pharma wins and pipeline
Book-to-bill and bookings shortfall
Revenue
$662.40M
▼ 8.6% YoY Diluted EPS
$-1.55
▼ 542.9% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Fortrea Holdings Inc. (FTRE) Q1 2024 Earnings Call Transcript
Balanced tone
Demand and Book-to-Bill
Commercial Transformation and Customer Mix
Capital Structure
Revenue
$662.10M
▼ 4.6% YoY Diluted EPS
$-1.13
▼ 907.1% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-11
Fortrea Holdings Inc. (FTRE) Q4 2023 Earnings Call Transcript
Positive tone
Bookings and commercial momentum
Spin-off completion and operating as standalone
Portfolio focus and divestiture
Revenue
$709.70M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Fortrea Holdings Inc. (FTRE) Q3 2023 Earnings Call Transcript
Revenue
$713.80M
▼ 6.4% YoY Diluted EPS
$-0.16
▼ 123.5% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Fortrea Holdings Inc. (FTRE) Q2 2023 Earnings Call Transcript
Revenue
$725.10M
▼ 8.6% YoY Diluted EPS
$0.35
▼ 53.3% YoY
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–19 of 19 webcasts
Key facts
CIK
1965040
CUSIP
34965K107
13F (30d)
373 filings
322 filers
Visit website
Investor relations